[ ![Lock Image](/themes/custom/cosmos/icons/lock-image.png) ](/arctic_media_access_logs_modal_form?media-hcp=12811) 

 

Description

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.



 

 

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.



 

 [ ![Lock Image](/themes/custom/cosmos/icons/lock-image.png) ](/arctic_media_access_logs_modal_form?media-hcp=12811) 

 [   Download (PDF 5.09 MB)  ](/arctic_media_access_logs_modal_form?media-hcp=12811)